---
schema_version: "secwatch.filing_event.v1"
accession: "0001295947-21-000027"
form_type: "8-K"
ticker: "PBH"
cik: "0001295947"
company_name: "Prestige Consumer Healthcare Inc."
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T21:18:31.092808+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Prestige Consumer Healthcare Q1 revenue $269.2M (+17.3%), EPS $1.14 (+32.5%); raises FY22 outlook

## Summary
- Revenue $269.2M, up 17.3% YoY; diluted EPS $1.14, up 32.5% vs prior year.
- North American OTC revenue $242.4M; International OTC $26.8M, up 43% from $18.7M.
- Raising FY22 guidance: revenue ~$1.045B+ (prev. $957-962M), adj. EPS $3.90+ (prev. $3.58+).
- TheraTears acquisition closed July 1, expected to add ~$40M revenue and $0.07 EPS to FY22.
- Net cash from ops $69.3M, free cash flow $67.8M; net debt ~$1.4B; refinanced term loan to 2028.

## SEC filing metadata
- accession: 0001295947-21-000027
- form_type: 8-K
- ticker: PBH
- cik: 0001295947
- company_name: Prestige Consumer Healthcare Inc.
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1295947/000129594721000027/0001295947-21-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1295947/000129594721000027/pbh-20210805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001295947-21-000027
- JSON: https://secwatch.observer/filing/0001295947-21-000027.json
- Plain text: https://secwatch.observer/filing/0001295947-21-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.